Skip to content

Author

M. Lussier

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol.

OBJECTIVE This article describes pharmacology, pharmacokinetics, safety, and efficacy data of enlicitide, the first Food and Drug Administration (FDA)-approved oral proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i). DATA SOURCES PubMed, Embase, Web of Science, and Cochrane were searched through July 17...

Rachel C. Lucas, M. Lussier, Azadeh Nasuhidehnavi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.